BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22235332)

  • 1. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells.
    Yamamura S; Saini S; Majid S; Hirata H; Ueno K; Deng G; Dahiya R
    PLoS One; 2012; 7(1):e29722. PubMed ID: 22235332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion.
    Wu X; Cheng YL; Matthen M; Yoon A; Schwartz GK; Bala S; Taylor AM; Momen-Heravi F
    J Exp Clin Cancer Res; 2021 Feb; 40(1):70. PubMed ID: 33596979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myc overexpression brings out unexpected antiapoptotic effects of miR-34a.
    Sotillo E; Laver T; Mellert H; Schelter JM; Cleary MA; McMahon S; Thomas-Tikhonenko A
    Oncogene; 2011 Jun; 30(22):2587-94. PubMed ID: 21297663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer.
    Dopeso H; Rodrigues P; Bilic J; Bazzocco S; Cartón-García F; Macaya I; de Marcondes PG; Anguita E; Masanas M; Jiménez-Flores LM; Martínez-Barriocanal Á; Nieto R; Segura MF; Schwartz S; Mariadason JM; Arango D
    Br J Cancer; 2018 Jan; 118(1):106-116. PubMed ID: 29206819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salicylate induces AMPK and inhibits c-MYC to activate a NRF2/ARE/miR-34a/b/c cascade resulting in suppression of colorectal cancer metastasis.
    Liu C; Rokavec M; Huang Z; Hermeking H
    Cell Death Dis; 2023 Oct; 14(10):707. PubMed ID: 37898661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.
    Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer progression.
    Ai J; Li J; Su Q; Ma H; He R; Wei Q; Li H; Gao G
    Gene Ther; 2022 Aug; 29(7-8):418-424. PubMed ID: 34226687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repression of SRF target genes is critical for Myc-dependent apoptosis of epithelial cells.
    Wiese KE; Haikala HM; von Eyss B; Wolf E; Esnault C; Rosenwald A; Treisman R; Klefström J; Eilers M
    EMBO J; 2015 Jun; 34(11):1554-71. PubMed ID: 25896507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth.
    Agarwal E; Altman BJ; Seo JH; Ghosh JC; Kossenkov AV; Tang HY; Krishn SR; Languino LR; Gabrilovich DI; Speicher DW; Dang CV; Altieri DC
    J Biol Chem; 2019 Jul; 294(27):10407-10414. PubMed ID: 31097545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ANP32B inhibition suppresses the growth of prostate cancer cells by regulating c-Myc signaling.
    Zhou C; Ma H; Yu W; Zhou Y; Zhang X; Meng Y; Chen C; Zhang J; Shi G
    Biochem Biophys Res Commun; 2024 Feb; 698():149543. PubMed ID: 38266312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth.
    Mukhopadhyay A; Hanold LE; Thayele Purayil H; Gisemba SA; Senadheera SN; Aldrich JV
    Cancer Biol Ther; 2017 Aug; 18(8):571-583. PubMed ID: 28692379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy.
    Abdelaal AM; Sohal IS; Iyer S; Sudarshan K; Kothandaraman H; Lanman NA; Low PS; Kasinski AL
    Oncogene; 2023 Sep; 42(40):2985-2999. PubMed ID: 37666938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivation of Myc transcription in the mouse heart unlocks its proliferative capacity.
    Bywater MJ; Burkhart DL; Straube J; Sabò A; Pendino V; Hudson JE; Quaife-Ryan GA; Porrello ER; Rae J; Parton RG; Kress TR; Amati B; Littlewood TD; Evan GI; Wilson CH
    Nat Commun; 2020 Apr; 11(1):1827. PubMed ID: 32286286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual peptides-modified cationic liposomes for enhanced Lung cancer gene therapy by a gap junction regulating strategy.
    Zhao Z; Wang W; Wang G; Huang Z; Zhou L; Lin L; Ou Y; Huang W; Zhang X; Wu C; Tao L; Wang Q
    J Nanobiotechnology; 2023 Dec; 21(1):473. PubMed ID: 38066528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective targeting of chemically modified miR-34a to prostate cancer using a small molecule ligand and an endosomal escape agent.
    Abdelaal AM; Sohal IS; Iyer SG; Sudarshan K; Orellana EA; Ozcan KE; Dos Santos AP; Low PS; Kasinski AL
    Mol Ther Nucleic Acids; 2024 Jun; 35(2):102193. PubMed ID: 38745855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises.
    Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
    bioRxiv; 2024 Jan; ():. PubMed ID: 38045265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423.
    Evelyn CR; Bell JL; Ryu JG; Wade SM; Kocab A; Harzdorf NL; Showalter HD; Neubig RR; Larsen SD
    Bioorg Med Chem Lett; 2010 Jan; 20(2):665-72. PubMed ID: 19963382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Glutathione S-transferase P1 Inhibits the Viability and Motility of Prostate Cancer via Targeting MYC and Inactivating the MEK/ERK1/2 Pathways.
    Wang XX; Jia HT; Yang H; Luo MH; Sun T
    Oncol Res; 2017 Jun; ():. PubMed ID: 28653607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gold-Based Pharmacophore Inhibits Intracellular MYC Protein.
    Ofori S; Gukathasan S; Awuah SG
    Chemistry; 2021 Feb; 27(12):4168-4175. PubMed ID: 33275307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mir-34: a new weapon against cancer?
    Misso G; Di Martino MT; De Rosa G; Farooqi AA; Lombardi A; Campani V; Zarone MR; Gullà A; Tagliaferri P; Tassone P; Caraglia M
    Mol Ther Nucleic Acids; 2014 Sep; 3(9):e194. PubMed ID: 25247240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.